Overview

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Status:
Recruiting
Trial end date:
2026-05-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Scientific Affairs, LLC
Treatments:
Cyclophosphamide
Fludarabine